Vyome Biosciences Pvt Ltd New Delhi
Vyome Biosciences Private Limited
Developer of medicines for treating skin diseases caused by resistant microbes.
Vyome Biosciences is a clinical stage dermatology based biopharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant acne, other opportunistic pathogens and antifungal agents. Vyome has put together a team of scientific and management experts from India and USA to deliver company’s growth plans. Vyome is co-founded by Shiladitya Sengupta, Venkateswarlu Nelabhotla (N. Venkat), Rajesh Gokhale and Rajeev Mantri. Vyome’s VB 1953, a novel drug targeting antibiotic resistant acne, had its IND (Investigational New Drug) application accepted by the US FDA in Jan 2016. Vyome also has a deep pipeline of NCEs unique in their ability to resist the development of resistance based on its patented Dual Action Rational Therapeutics (DART™) technology, which are in pre-clinical stage. In addition, Vyome has clinically proven products to treat scalp & skin seborrheic dermatitis, for which Vyome is currently pursuing partnering discussion globally.